Microplasmin Effective in Two Phase 3 Trials

A single injection of microplasmin (ThromboGenics NV) was effective for the treatment of symptomatic vitreomacular adhesion (VMA), according to the pooled results of two phase 3 trials, TG-MV-006 and TG-MV-007. The findings of the trials, referred to...